ADMA Biologics Commences Pivotal Phase III Clinical Study of RI-002 in PIDD ... PipelineReview.com (press release) HACKENSACK, NJ, USA I March 7, 2013 I ADMA Biologics, Inc. (ADMA), a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases, ... |
